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AbstrACt
Objective The aim of this study was to use a sampling-
based approach to obtain estimates of retention in HIV 
care before initiation of antiretroviral treatment (ART), 
corrected for outcomes in patients who were lost 
according to clinic registers.
Design Retrospective cohort study of HIV-positive 
individuals not yet eligible for ART (CD4 >500).
setting Three urban and three rural HIV care clinics 
in Uganda; information was extracted from the clinic 
registers for all patients who had registered for pre-ART 
care between January and August 2015.
Participants A random sample of patients who were 
lost according to the clinic registers (>3 months late to 
scheduled visit) was traced to ascertain their outcomes.
Outcome measures The proportion of patients lost from 
care was estimated using a competing risks approach, 
first based on the information in the clinic records alone 
and then using inverse probability weights to incorporate 
the results from tracing. Cox regression was used to 
determine factors associated with loss from care.
results Of 1153 patients registered for pre-ART care 
(68% women, median age 29 years, median CD4 count 
645 cells/µL), 307 (27%) were lost according to clinic 
records. Among these, 195 (63%) were selected for 
tracing; outcomes were ascertained in 118 (61%). 
Seven patients (6%) had died, 40 (34%) were in care 
elsewhere and 71 (60%) were out of care. Loss from 
care at 9 months was 30.2% (95% CI 27.3% to 33.5%). 
After incorporating outcomes from tracing, loss from care 
decreased to 18.5% (95% CI 13.8% to 23.6%).
Conclusion Estimates of loss from HIV care may be too 
high if based on routine clinic data alone. A sampling-
based approach is a feasible way of obtaining more 
accurate estimates of retention, accounting for transfers to 
other clinics.
IntrODuCtIOn  
Access to antiretroviral therapy (ART) has 
expanded considerably in sub-Saharan Africa 
(SSA), with 12 million people in the region 
receiving ART in 2016.1 With the UNAIDS 
90-90-90 targets (90% of HIV-positive indi-
viduals know their status, 90% of those 
diagnosed are on ART and 90% of those on 
ART are virally suppressed by 2020), more 
HIV-positive individuals are expected to be on 
ART and attain viral suppression.2–4 However, 
although treatment coverage in SSA doubled 
between 2010 and 2015, estimated coverage 
was still only 47% in 2015, and HIV-related 
mortality remains high, partly due to loss 
from care.1 2 
Major gaps in HIV treatment programmes 
include linking individuals who test HIV posi-
tive to care and prompt initiation of ART. 
Previous WHO treatment guidelines were 
based on CD4 count thresholds, with pre-ART 
care focused on immunological monitoring 
until individuals became eligible for ART. A 
2012 systematic review of retention in HIV 
care in SSA found a median of 57% of indi-
viduals returned for CD4 count results after 
strengths and limitations of this study
 ► Most studies that use tracing to estimate retention in 
care focus on HIV-positive individuals on antiretrovi-
ral   treatment (ART); this is one of few studies to ap-
ply these methods in the period before ART initiation.
 ► A sampling-based approach is feasible and provides 
an opportunity to obtain more accurate estimates of 
retention in HIV care programmes in resource-lim-
ited settings.
 ► Outcomes were not ascertained in all patients who 
were traced, so individuals who were traced suc-
cessfully may not be representative of all who were 
lost.
 ► The follow-up time was relatively short, so some 
patients who were considered lost according to the 
clinic registers may have returned to the clinic at a 
later date.
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testing HIV positive, and among those who received their 
results, 45% remained in care until they became eligible 
for ART.5 Even among those who were ART eligible, only 
a median of 66% initiated ART.5
WHO released new HIV treatment guidelines in 2015, 
recommending that ART be offered to all HIV-positive 
individuals irrespective of CD4 count.6 If widely imple-
mented, the ‘treat all’ approach would contribute signifi-
cantly to achieving the 90-90-90 goals. As of end 2016, 
many countries in SSA had begun implementing the new 
guidelines. However, several countries had introduced 
the guidelines only in selected treatment sites, and others 
had not yet adopted the new policy.1 Scale-up of ART 
treatment for all HIV-positive people in resource-limited 
settings will require broad health systems strengthening, 
which in practice may mean that, for budgetary or other 
practical reasons, some clinics may still use CD4 counts to 
prioritise starting treatment. Uganda officially rolled out 
the test and treat guidelines in November 2016. By end 
2017, nearly all government clinics had implemented test 
and treat. However, in practice, priority for ART initia-
tion is given to existing patients in pre-ART care. Further-
more, ART ‘stock outs’ are still common, so individuals 
who are newly diagnosed are likely to have some period 
of pre-ART care. In March 2017, an estimated 6% of 
HIV-positive persons who were enrolled in HIV care were 
not on ART.7 In addition, 48% of men who had tested 
HIV positive have not yet initiated ART.7
Under the ‘treat all’ guidelines, many individuals who 
are entering HIV care will have high CD4 counts and be 
asymptomatic, and therefore face different barriers to 
starting ART. Losses between testing HIV positive and 
ART initiation are still likely to remain. Obtaining accu-
rate estimates of loss from care and outcomes in this stage 
will be important for evaluating the impact of the ‘treat 
all’ guidelines, and for designing interventions to improve 
retention and increase the numbers starting ART.8
Standard estimates of retention consider those who 
are lost to represent disengagement from care. However, 
many of those lost may include transfers to other care 
centres.9 10 In rural Uganda, estimates of patient reten-
tion 3 years after initiating ART increased from 60% to 
85% when corrected for outcomes among those who were 
lost.9 11 Therefore, estimates of retention that consider 
patients who are lost from care to have disengaged 
from care are biased, and may result in misdirection of 
resources at the clinic and national levels.
We used a sampling-based approach to obtain more 
accurate estimates of loss from pre-ART care among 
HIV-positive individuals attending clinics in Uganda who 
were not yet eligible for ART. This approach involves 
tracing a sample of lost patients and using a weighted 
analysis to correct the estimates of retention in the entire 
clinic population, with the assumption that the traced 
patients are representative of all who were lost.12–14 We 
also explore the effect of this approach on estimates of 
mortality and factors associated with loss from care before 
ART initiation.
MethODs
study setting
This was a retrospective cohort study of patients who had 
registered in pre-ART HIV care at six government clinics 
in Uganda: three urban Kampala city municipal clinics 
(Kisenyi, Kawala and Kitebi), which are managed by the 
Kampala City Council Authority (KCCA), and three rural 
health centres in Hoima and Kibaale districts in western 
Uganda, which are run by the Uganda Ministry of Health. 
The three urban clinics are level IV health centres, which 
have a target catchment population of 100 000. Kisenyi is 
the largest of these and serves a particularly economically 
impoverished area. The rural facilities included one level 
IV (Kiogorobya) and one level III (Dwoli) health centre 
in Hoima district, and Kagadi District Hospital in Kibaale 
district. Hoima district had an estimated population of 
574 000 in the 2014 census, and Kibaale had an estimated 
population of 789 000.
All six facilities are supported by the Infectious Diseases 
Institute (IDI), Makerere University and offer integrated 
HIV testing and care facilities, provision of ART and labo-
ratory support. Most persons attend the HIV counselling 
and testing facilities as walk-ins. Individuals who test posi-
tive are referred for care within the clinic, or a preferred 
alternate facility, for immediate CD4 testing. Individuals 
are registered at the clinic at the time of initiating CD4 
testing. They are then asked to return to the clinic within 
2 weeks for their CD4 results. At the time of the study 
(2015), individuals who were not yet eligible for ART 
were enrolled in a general pre-ART HIV care programme, 
and visited the clinic every 3 months for routine clinic 
check-ups and cotrimoxazole prophylaxis. In 2015, the 
CD4 count threshold for ART initiation was ≤500 cells/
µL; however, in practice, priority was given to individ-
uals with CD4 counts <350. The three Kampala clinics 
are among seven KCCA clinics supported by IDI; in June 
2015, there were 33 514 HIV-positive persons receiving 
HIV care services in these facilities, of whom 87% were 
on ART.15
study design
A list of all individuals who tested HIV positive between 
January and May 2015 (Kampala clinics) and January 
and August 2015 (rural clinics) and were not yet eligible 
for ART was obtained from the routine clinic records. 
Sociodemographic and routine clinical data for patients 
attending the Kampala clinics were extracted using the 
electronic patient records system (OpenMRS). For 
patients attending the rural clinics, the information was 
manually extracted from the paper-based clinic records 
and entered into an Access database. Patients were then 
classified as either (1) still in care, (2) transferred out to 
another clinic, (3) died or (4) lost to follow-up, based on 
the information available from the clinic records. Patients 
were counted as lost to follow-up if they were three or 
more months late for their last scheduled visit at the 
clinic, and not known to have transferred out or to have 
died.
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From the sampling frame of all patients who were clas-
sified as lost, a random sample was selected, separately for 
urban clinics and rural clinics, for intensive tracing. The 
size of the sample was based on practical considerations 
of how many patients could be traced at each clinic with 
available resources, rather than on formal sample size 
calculations.
Tracing was done between November 2015 and March 
2016 in both the urban and rural clinics. Tracers 
attempted to contact patients through phone calls 
and home visits, using addresses and locator forms 
containing secondary phone numbers, areas of resi-
dence and a map to the area of residence. For patients 
who could not be contacted through phone calls, home 
visits using locator forms were used; at least three 
visit attempts were made before declaring the patient 
unreachable.
Patients who were successfully traced were asked 
to provide information about their current HIV care 
status: whether they were registered elsewhere and were 
attending another clinic, whether they had started ART 
elsewhere and reasons for withdrawing from HIV care if 
not attending any HIV care facility. Patient deaths were 
ascertained through an interview with a close informant.
Individuals were considered to have disengaged from 
care if they had not registered at any other clinic and had 
not returned to the clinic where they were originally regis-
tered for more than 3 months after their last scheduled 
visit. Individuals who said they were purchasing cotrimox-
azole directly from the pharmacy (ie, not under clinician’s 
care) or they obtained drugs through relatives/friends 
were also considered to have disengaged from care. Indi-
viduals who reported to have registered at another clinic 
were asked the name of the other clinic, the date of their 
next appointment and for evidence of registration such 
as a patient card with a current appointment date. Those 
who had a current patient card, or gave a valid name of 
an HIV care clinic with a current appointment date, were 
considered to be in care.
Interviews were conducted by trained nurse coun-
sellors, all of whom had previous research experience. 
Information was collected using a standard structured 
questionnaire. The nurse counsellors made the contact 
attempts by telephone and traced urban patients at their 
homes if the information on the locator form was suffi-
cient. Many of the rural patients could not be reached 
by telephone, and the information on the locator forms 
was inadequate. Therefore, in the rural clinics, ‘expert’ 
patients from each clinic were paired with the nurse inter-
viewers to help trace patients in the community. Expert 
patients also helped with tracing in the urban clinics, 
for patients who could not be found through the locator 
forms. Expert patients serve as community volunteers at 
the clinic and offer support to fellow patients in HIV care. 
They are familiar with the surrounding community and 
are often called on by the clinic to help trace persons on 
ART who have missed their visits.
Statistical analysis
Descriptive statistics (proportions, means, medians 
and IQRs) were used to summarise baseline character-
istics. Characteristics of patients who were retained in 
pre-ART care and those who were lost were tabulated and 
compared using χ2 tests, with the Rao-Scott correction to 
account for correlation within clinics. In addition, char-
acteristics of patients who were selected for tracing and 
traced successfully were compared with those who were 
selected but could not be found.
First, using only the information available from the 
clinic records, the proportion of patients who were lost 
from pre-ART care was estimated using a cumulative 
incidence approach, where deaths known to the clinics 
were treated as a competing risk. Observation time 
began on the date of registration at the clinic (ie, the 
date of presenting for CD4 testing after HIV diagnosis) 
and ended at the earliest of the date of known transfer 
out, death, loss from care (defined as 3 months after last 
missed appointment) or review of the clinic records (for 
individuals who were still in care). Patients who initi-
ated ART were censored on the date of ART initiation. 
Then, a corrected analysis was conducted using the same 
approach but incorporating the outcomes obtained from 
tracing. The outcomes of patients who were successfully 
traced were weighted using inverse probability weights, 
calculated as the inverse proportion of patients who 
were successfully traced among all patients who were 
lost. Patients who could not be found, or who were not 
selected for tracing, were given a weight of 0. Patients who 
were still in care according to the clinic registers were 
given a weight of 1. Weights were calculated separately 
for each clinic. For example, suppose that in a clinic with 
100 patients of whom 30 were lost, 10 were successfully 
traced and 6 were found to be still in care, the weights 
for the patients who were traced would be 30/10=3. The 
corrected estimate for the proportion in care would be 
calculated as: (70×1+6 (found to be still in care)×3)/
(70×1+6×3+4 (found to be out of care)×3)=88/100. For 
individuals who were traced and found to still be in care, 
observation time was considered to end at the date of 
interview. Individuals who were traced and found to be 
alive but not in care were considered to have been lost 3 
months after their last missed appointment at the original 
clinic.
A sensitivity analysis was also done: first, we assumed 
that all individuals who were traced and not found were 
alive and in care elsewhere; second, we assumed that all 
patients who were not found were alive but not in care. 
CIs for the weighted estimates were obtained through 
bootstrapping using percentiles of the bootstrap distribu-
tion with 2000 replications.
Cox proportional hazards models were fitted to 
examine factors associated with loss from care, using data 
from the clinic registers alone and in a weighted analysis 
after incorporating results from tracing. Robust SEs were 
used to account for correlation within clinics. Owing to 
the small number of covariates available, all variables 
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were included in the final multivariate model. In the 
rural clinics, data on clinical covariates were often missing 
from the patient records; therefore, the analysis of clin-
ical covariates was restricted to patients from the urban 
clinics. The appropriate functional forms of continuous 
covariates were explored using low order polynomials 
(quadratic and cubic forms). All analyses were done using 
Stata V.14.2 (Stata Corp, College Station, Texas, USA).
ethics
Patients give informed consent at the time of registration 
in HIV care at the clinics, to be traced in case they miss 
their appointments. Patients who were traced success-
fully gave additional written or oral (phone interviews) 
informed consent for participation in the current study.
results
Between the period of January and August 2015, 1153 
individuals had registered in pre-ART care at the six 
clinics: 925 (80.2%) at the urban clinics and 228 (19.8%) 
at the rural clinics. A total of 307 (26.6%) individuals 
were classified as lost from care (table 1); 207 from the 
urban clinics (22.4% of urban patients) and 100 from 
the rural clinics (43.9% of rural patients). A random 
sample of 195 (63.5% of those lost) patients was selected 
for tracing (116 from the urban clinics and 79 from the 
rural clinics) and 118 (60.5%) were successfully traced. 
Seventy patients had face-to-face interviews in the clinics, 
20 had telephone interviews and 28 had home visits.
The median (IQR) age of all patients who registered in 
pre-ART care was 29 (24‒35) years; the majority (68.2%) 
were women, and the median (IQR) CD4 count was 645 
(529‒834) cells/µL. CD4 counts were missing for 15% of 
patients (10% of those still in care and 27% of those who 
were lost); all missing data were from the rural clinics. 
Characteristics of patients who were still in care were 
generally similar to those who were lost, but there was 
some evidence that those who were lost were most likely 
to be from rural clinics and to have higher CD4 counts 
(table 1). Among the 195 patients who were selected for 
tracing, there was no evidence of a difference in the char-
acteristics between those who were successfully traced and 
those who were not found. Of those who were successfully 
traced, 40 (33.9%) were found to be actively in care (ie, 
had re-registered at another clinic and were keeping up 
with their clinic appointments) and 71 (60.2%) were out 
of care. Seven (5.9%) individuals were found to have died 
after having left care.
At 9 months, the cumulative incidence of loss from care 
based on the clinic registers was 30.2% (95% CI 27.3% 
to 33.5%; figure 1). After incorporating outcomes from 
those who were successfully traced, loss from care reduced 
to 18.5% (95% CI 13.8% to 23.6%). From the sensitivity 
analysis, assuming that the individuals who were traced 
but not found were all in care, then loss was 14.9% (95% 
CI 10.8% to 19.6%). Assuming that these patients were all 
out of care, then loss from care increased to 38.5% (95% 
CI 31.5% to 45.7%). Loss from care was higher in rural 
than urban clinics (46.1% vs 25.8%, respectively, based on 
the clinic registers). When corrected for the outcomes of 
those who were traced, loss from care was 28.8% (95% CI 
19.9% to 37.5%) in the rural clinics and 15.3% (95% CI 
9.9% to 21.5%) in the urban clinics.
Based on the information available from the clinic 
registers alone, no patients were known to have died. 
After tracing, seven patients were found to have died. 
After incorporating the deaths that were found through 
tracing, the cumulative incidence of mortality at 9 months 
was estimated to be 1.6% (95% CI 0.5% to 3.0%).
In both the uncorrected and corrected analysis of 
factors associated with loss from care, there was strong 
evidence that patients from rural clinics were more 
likely to be lost from care than those from urban clinics 
(adjusted(a)HR (uncorrected)=1.95, 95% CI 1.68 to 
2.27, p<0.001; aHR (corrected)=2.02, 95% CI 1.49 to 
2.73, p<0.001; table 2). There was some evidence that 
older patients were less likely to be lost from care than 
younger patients (aHR (uncorrected)=0.79 for each 
10-year increase in age, 95% CI 0.66 to 0.94, p=0.007; 
aHR (corrected)=0.71; 95% CI 0.54 to 0.93, p=0.01). In 
the corrected analysis, but not in the uncorrected, there 
was also weak evidence that men were more likely to be 
lost from care.
Among patients from the urban clinics, in the uncor-
rected analysis, weight at registration was the only clinical 
characteristic associated with loss from care. Loss from 
care decreased with increasing weight to around 60 kg, 
and then increased. After incorporating outcomes from 
the successfully tracked patients, weight at registration 
was still associated with loss from care, but the direction 
of the association had changed, with the risk of loss from 
care increasing slightly with increasing weight to around 
60 kg, and then decreasing (table 2).
Among the 71 patients who were successfully tracked 
and found not to be seeking care elsewhere, the main 
reasons for stopping care were that they lacked money 
for transport (37%), that they did not feel unwell (27%) 
or that they had moved to places without an HIV care 
facility (27%) (table 3). Patients also reported that they 
lacked time (15%), purchased cotrimoxazole from other 
sources (14%) or did not believe that they were HIV posi-
tive (11%). The main reasons for stopping care among 
urban patients was not feeling unwell (41%) or having 
moved (39%). Among rural patients, the main reasons 
were lack of money for transport (50%) or that the clinic 
was too far away (43%).
Among the 40 patients who reported being in care at 
another clinic, the main reasons for changing clinics 
was that the new clinic was closer to work or home 
(45%), they lacked money for transport (25%) or the 
new clinics had less waiting time (17%). The new clinic 
being closer was cited as the main reason for changing 
for both urban and rural patients (52% and 35%, 
respectively).
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DIsCussIOn
Much of the research that has been done regarding correc-
tion of estimates of retention in HIV care has concentrated 
on HIV-positive individuals on ART. This study looked at 
individuals who had recently received an HIV diagnosis 
but were not yet eligible for ART. Based on the information 
Figure 1 Uncorrected and corrected cumulative incidence of loss from care among patients with CD4 >500 registered for HIV 
care at six clinics.
Table 2 Factors associated with loss from care, estimated from Cox proportional hazards models, based on data in clinic 
registers (uncorrected) and corrected for the outcomes among patients who were successfully traced
Characteristics Uncorrected HR* (95% CI) P values Corrected HR* (95% CI) P values
Sociodemographic
Sex 0.38 0.07
  Female 1
  Male 1.17 (0.82 to 1.68) 1.39 (0.97 to 1.99)
Age per 10 years 0.007 0.01
0.79 (0.66 to 0.94) 0.71 (0.54 to 0.93)
Location <0.001 <0.001
  Urban 1 1
  Rural 1.95 (1.68 to 2.27) 2.02 (1.49 to 2.73)
Clinical†
CD4 count (per 100 cells) 0.22 0.41
1.04 (0.98 to 1.10) 1.05 (0.93 to 1.20)
Weight per 10 kg‡ <0.001 <0.001
  Linear term 0.94 (0.80 to 1.11) 1.03 (0.74 to 1.42)
  Quadratic term 1.03 (1.02 to 1.04) 0.94 (0.90 to 0.98)
*Sociodemographic variables adjusted for all sociodemographic variables in the table. Clinical variables adjusted for all variables in the table.
†Analysis of associations with clinical variables restricted to urban patients.
‡Weight is scaled (divided by 10) and centred on mean weight in the analysis.
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from the clinic registers alone, loss from care was nearly 65% 
higher than after correcting for outcomes among individ-
uals who were traced. We found that a third of the patients 
who were considered lost were continuing to access care at 
another clinic (silent transfers). We also identified deaths 
that had not been reported to the clinic. Other studies that 
have used a sampling-based approach to correct estimates of 
retention among HIV-positive individuals on ART have had 
similar findings.12 16 17
A study among HIV-positive people in pre-ART care at 
two large clinics in Uganda in 2008–2011 found that loss 
from care after 2.5 years was 30.5% but decreased to 11.8% 
after correcting for outcomes in a sample of lost patients.18 
These figures are much lower than we found in our study 
in 2015, particularly in the rural clinics where corrected 
estimates of loss from care after 9 months were still 28.8%. 
The tracing period in our study was shorter and our defini-
tion of loss from care was more restrictive (3 months late to 
appointment vs 6 months late). Furthermore, some of the 
clinics in our study were smaller and more rural, so factors 
such as lack of transport or distance to the clinic may have 
presented greater barriers to retention. In the rural areas, 
patients often have to travel more than 10 km on foot or 
bicycle to get to the clinics. Lastly, the CD4 threshold for 
ART eligibility in the earlier study was ≤350, versus ≤500 in 
2015, so a larger proportion of patients in our study may 
have been asymptomatic and thus less motivated to remain 
in care.
Our estimates of retention, even after correction, are 
in line with previous studies in SSA that have shown poor 
retention among patients in pre-ART care. A recent review 
found a median of 53% of patients who had linked to 
pre-ART care were retained until the study endpoint.19 Even 
among patients who have been identified as ART eligible, a 
not insignificant proportion may be lost before starting ART. 
A study of ART-eligible patients at a clinic in Uganda found 
20% did not start ART within a year, with 8% dying while 
waiting to initiate ART.11 Two separate reviews of retention 
in HIV care in SSA found that around a third of patients who 
were eligible for ART were lost before starting treatment.5 20 
Factors associated with loss from care in this stage include 
facility-level barriers such as requirements for multiple clinic 
visits, inflexible clinic hours, lengthy waiting times and poor 
quality of care, and individual-level barriers such as fear of 
HIV disclosure, or limited understanding of HIV.21
With the new WHO ‘treat all’ guidelines, all individuals 
will be eligible to start ART immediately, but in practice 
there is likely to be a delay between linking to care after 
testing positive and initiating treatment. Removing the CD4 
eligibility threshold may increase the number of patients 
attending the clinics, which can put a strain on already over-
burdened healthcare systems. Many of the same barriers to 
Table 3 Reported reasons for leaving care or changing clinics among 111 patients who were traced and found alive
Reason for no longer attending clinic
No longer in care
Urban (n=41) Rural (n=30) All (n=71)
Lack money for transport 11 (26.8%) 15 (50.0%) 26 (36.6%)
Does not feel sick 17 (41.5%) 2 (6.7 %) 19 (26.8%)
Travelled/moved away 16 (39.0%) 3 (10.0%) 19 (26.8%)
Health centre is far away 5 (12.2%) 13 (43.3%) 18 (25.4%)
Lack time 8 (19.5%) 3 (10.0%) 11 (15.5%)
Gets cotrimoxazole from other sources 7 (17.1%) 3 (10.0%) 10 (14.1%)
Doubts HIV status 4 (9.8 %) 4 (13.3%) 8 (11.3%)
Fear of being seen at the HIV clinic 0 (0.0 %) 5 (16.7%) 5 (7.0 %)
Does not like drugs/side effects 4 (9.8 %) 1 (3.3 %) 5 (7.0 %)
Using herbal/traditional medicines 0 (0.0 %) 3 (10.0%) 3 (4.2 %)
Other reason 3 (7.3 %) 2 (6.7 %) 5 (7.0 %)
Reason for changing clinics
In care at another clinic
Urban (n=23) Rural (n=17) All (n=40)
Closer to work 12 (52.2%) 6 (35.3%) 18 (45.0%)
Lack of money for transport 6 (26.1%) 4 (23.5%) 10 (25.0%)
Less waiting time 7 (30.4%) 0 (0.0 %) 7 (17.5%)
Lack time 5 (21.7%) 1 (5.9 %) 5 (12.5%)
Friends/family attend 3 (13.0%) 0 (0.0 %) 3 (7.5 %)
Fear of being seen at the first clinic 3 (13.0%) 1 (5.9 %) 3 (7.5 %)
Better service 1 (4.3 %) 1 (5.9 %) 2 (5.0 %)
Other reason 1 (4.3 %) 4 (23.5%) 5 (12.5%)
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ART initiation will remain under ‘treat all’ unless the process 
of starting ART is made more efficient. For successful imple-
mentation of the new guidelines, it will be essential to have 
accurate estimates of the proportion of people who disen-
gage from care in the period before starting ART.
In our study, most of the reported reasons for leaving 
care were economic (lack of money for transport, distance 
from the clinic) or health systems factors (moving to a loca-
tion without an HIV care facility). These factors have been 
commonly cited in other studies and are a challenge to 
providing lifelong HIV care in resource-limited settings. A 
systematic review of linkage to and retention in HIV care 
found that transport costs and distance were two of the 
main barriers to retention in pre-ART care.21 A considerable 
number of patients reported obtaining cotrimoxazole from 
other sources, presumably in response to the challenges 
they faced attending the clinic. Psychological factors such 
as feeling well, or not believing that one was HIV positive, 
were also cited as reasons for leaving care, especially among 
urban patients. As has been reported in other studies, we 
found that younger patients were more likely to be lost 
from care.21 These findings suggest that a combination of 
interventions may be required to improve retention in care.
We used a pragmatic approach to correct our esti-
mates of loss from care, arithmetically upweighting the 
outcomes of patients who were tracked successfully to 
represent those of patients who were lost. Other methods 
have been proposed for incorporating these outcomes, 
including using regression models to estimate the 
inverse probability weights, and multiple imputation 
in conjunction with the ascertained outcomes. Simula-
tions have shown that these strategies all provide less 
biased results than the standard uncorrected approach 
that is used in many epidemiological studies.22
Our study has several limitations. We traced only a sample 
of patients who were lost and were able to find 61% of those 
who were selected for tracing. The individuals that we found 
may not have been representative of all patients who were 
lost. Although there was no evidence that the characteristics 
of those who were successfully traced were different from 
those who were not found, our small sample size means that 
we may not have had power to detect true differences if they 
existed, and residual selection bias may still remain. In addi-
tion, our sample size was based on practical considerations, 
rather than the power to detect a particular effect size. Our 
analysis of predictors of loss from care was underpowered 
to detect anything except large effects, particularly in our 
analysis of clinical factors, which was restricted to the urban 
clinics. Similarly, our estimates of retention in care, and of 
mortality, are less precise than they would have been with a 
larger sample. Furthermore, there were relatively few deaths 
so our sample size may not have been adequate to obtain an 
accurate estimate of mortality. We looked at loss from care 
over a fairly short period (9 months); it is possible that some 
of the individuals defined as lost based on the clinic regis-
ters would have returned to the clinic at a later date. For 
the individuals who were successfully traced, we relied on 
self-report to define whether an individual was still in care 
at another clinic, which may have led to over-reporting of 
care. Our analysis of factors associated with loss from care 
was limited by the small number of covariates and the large 
amount of missing data in the clinic databases particularly 
from the rural areas. Our findings from government clinics 
in Uganda may not be generalisable across all HIV treatment 
programmes in SSA, where reasons for disengagement from 
care, and outcomes after disengagement, may differ.
In summary, we found that estimates of loss from pre-ART 
care using a sampling-based approach were substantially 
lower than those based on the clinic registers alone. Reten-
tion was much lower in rural clinics than in urban clinics 
and was in line with previous reports of pre-ART retention 
in SSA. Structural factors were a key barrier to retention. 
These findings may have implications for the successful 
implementation of the ‘treat all’ guidelines and retention 
in care among individuals with high CD4 counts in similar 
resource-limited settings.
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